Safety and Efficacy of GTS21 in Adults With Attention-deficit Hyperactivity Disorder

Attention Deficit Hyperactivity Disorder Clinical Trial

Official title:

A Double-Blind, Randomized, Proof-of-Concept Crossover Trial to Assess the Effects of GTS21 on Cognitive Function, Clinical Symptoms, and Adverse Events in Adults Diagnosed With Attention-Deficit Hyperactivity Disorder

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00419445
• Other study ID #: GTS21-202
• Status: Completed
• Phase: Phase 1/Phase 2
• First received: January 4, 2007
• Last updated: August 16, 2010
• Start date: February 2007
• Est. completion date: January 2008

Study information

• Verified date: August 2010
• Source: CoMentis
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

This study will be a randomized, double-blind, placebo-controlled crossover study to assess the effects of GTS21 (25 mg three times a day (tid), 75 mg tid, 150 mg tid) compared to placebo in non-smoking adults aged 18-55 with a diagnosis of ADHD, any subtype.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 37
• Est. completion date: January 2008
• Est. primary completion date: January 2008
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 55 Years

Eligibility

Inclusion Criteria:

• Male or female between the ages of 18-55, inclusive.

• Diagnostic and Statistical Manual for the Classification of Mental Disorders, Fourth Edition (DSM-IV) criteria for ADHD, any subtype, based on a detailed psychiatric evaluation including the Conners' Adult ADHD Interview for DSM-IV (CAADID) and the Structured Clinical Interview for DSM-IV (SCID).

• A minimum Total ADHD Symptoms Index score of 28 on the clinician administered CAARS.

• A Clinical Global Impressions-Severity (CGI-S) score of = 4 at Screening.

• Normal or clinically insignificant ECG and clinical laboratory (e.g., liver enzymes, complete blood count, etc.) findings at Screening.

• Intellectual function at age-appropriate levels, as deemed by the Investigator.

• Supine systolic and diastolic blood pressure measurements < 140 and < 90, respectively, at Screening.

• Written, signed and dated informed consent for the patient to participate in the study must have been given by the patient.

• Females of child-bearing potential must have had a negative serum beta human chorionic gonadotropin (HCG) pregnancy test at Screening and be practicing double-barrier methods of contraception, if sexually active and for 30 days following administration of any study drug.

• Male patients who were sexually active must have agreed to use a reliable form of contraception during the study and for 30 days following administration of any study drug.

• Be fluent in English (speaking, writing and reading).

Exclusion Criteria:

• Any current, controlled (requiring a prohibited medication) or uncontrolled, comorbid psychiatric diagnosis (except simple phobias), all major depressive disorders [dysthymia and mood disorder not otherwise specified (NOS) allowed unless medication required],and any severe comorbid Axis II disorders or severe Axis I disorders such as Post Traumatic Stress Disorder, bipolar illness, psychosis, obsessive-compulsive disorder, substance abuse disorder, or other symptomatic manifestations that, in the opinion of the Investigator, contraindicated treatment with GTS21 or confound efficacy or safety assessments.

• Any condition or illness (including clinically significant abnormal laboratory values) which, in the opinion of the Investigator, represented an inappropriate risk to the patient and/or could confound the interpretation of the study.

• Regular use of nicotine products (including 90 days before Screening), including smoking, transdermal patch, chewing tobacco, etc. (verified via salivary cotinine levels at Screening).

• Current use of any prohibited medication or other medications, including herbal supplements, that have central nervous system (CNS) effects or affect cognitive performance, such as sedating antihistamines and decongestant sympathomimetics (bronchodilators were permitted).

• Use of another investigational product or participation in a clinical study within 30 days prior to Screening.

• Body Mass Index (BMI) > 32.

• Known or suspected allergy, hypersensitivity, or clinically significant intolerance to nicotine or nicotinic agonists.

• Clinically important abnormality on urine drug screen (excluding the patient's current ADHD stimulant, if applicable) at Screening.

• Pregnant or currently lactating.

• Patients that had previously been enrolled into this study and subsequently withdrawn.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Attention Deficit Disorder with Hyperactivity
• Attention Deficit Hyperactivity Disorder
• Hyperkinesis

Intervention

Drug:
• GTS21/Placebo

Locations

Country	Name	City	State
United States	Duke University Medical Center	Durham	North Carolina
United States	George Washington University Medical Center	Washington	District of Columbia

Sponsors (1)

Lead Sponsor	Collaborator
CoMentis

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	To Assess the Safety and Tolerability of GTS21 (25 mg Tid, 75 mg Tid, 150 mg Tid).	The proportion of subjects with Treatment Emergent Adverse Events.	Baseline to study completion	Yes

External Links

•   Link